Open AccessPathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
Author(s) -
Matthew G. Davey,
Ferdia Browne,
Nicola Miller,
Aoife Lowery,
Michael J. Kerin
Publication year - 2022
Publication title -
bjs open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.974
H-Index - 9
ISSN - 2474-9842
DOI - 10.1093/bjsopen/zrac028
Subject(s) - breast cancer , hazard ratio , medicine , oncology , confidence interval , human epidermal growth factor receptor 2 , meta analysis , biomarker , cancer , biology , biochemistry
Achieving a pathological complete response (pCR) is believed to correlate with oncological outcomes in human epidermal growth factor receptor-2-positive (HER2+) breast cancer. However, informed estimation of this survival advantage is often difficult to quantify. The aim of this study was to evaluate the role of pCR as a biomarker of survival in patients treated with neoadjuvant therapies for HER2+ breast cancer.